CLEARPOINT NEURO INC
CLPTNASDAQTrading Snapshot
- Day Range
- $10.65 β $11.97
- 52-Week Range
- $8.27 β $27.27
- Volume (shares)
- 1,249,798
- Avg Volume (shares)
- β
- Shares Outstanding
- 30.5M
- Next Earnings
- 2027-03-03
Fundamentals Snapshot
- Annual Revenue
- $37M
- Last Q Revenue
- $11M
- P/E Ratio
- β
- P/S Ratio
- 7.6x
- EPS (TTM)
- $-1.18
- Dividend Yield
- β
- Dilution (1yr)
- +4.8%
CLEARPOINT NEURO INC
CLPTAbout CLEARPOINT NEURO INC
ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated systems that facilitate minimally invasive brain surgeries, guided by real-time magnetic resonance imaging (MRI) during the procedure. Among its core offerings is the ClearPoint system, designed for the precise placement of deep brain stimulation electrodes, biopsy needles, and for the controlled infusion of medications and laser catheters directly into the brain. It also provides the ClearPoint Neuro Navigation System, which is specifically engineered for MRI suite environments. ClearPoint Neuro maintains strategic partnerships and licensing agreements with prominent institutions and companies, including Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and the University of California, San Francisco. Initially established in 1998 and headquartered in Solana Beach, California, the company operated as MRI Interventions, Inc. before rebranding to ClearPoint Neuro, Inc. in February 2020.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPT
NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ClearPoint Neuro, Inc. ("ClearPoint" or the "Company") (NASDAQ: CLPT). Such investors are advised to contact Daniell

What ClearPoint Neuro (CLPT) Said on Its Q3 Earnings Call
ClearPoint Neuro NASDAQ: CLPT reported third-quarter 2026 revenue growth of 36% as sales increased across its biologics and drug-delivery, neurosurgery navigation and therapy, and capital equipment and software businesse

ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Misses Revenue Estimates
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.21 per share a year ago.

ClearPoint Neuro, Inc. (CLPT) Q3 2026 Earnings Call Transcript
ClearPoint Neuro, Inc. (CLPT) Q3 2026 Earnings Call Transcript

ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026
SOLANA BEACH, CA / ACCESS Newswire / October 14, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, t

CLPT Investors with $100,000 in Losses Have Opportunity to Join ClearPoint Neuro, Inc. Fraud Investigation with SBS Law
[url="]Schall, Brown and Schwartz[/url] LLP (Γ’ΒΒSBSΓ’ΒΒ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv